The Plain Prescription Prices Act would require the federal health agency to regulate price disclosures in direct-to-consumer advertising for prescription drugs and certain biologics. Within one year of enactment, the Secretary of Health and Human Services, acting through the Administrator of the Centers for Medicare & Medicaid Services, must promulgate rules requiring truthful, non-misleading textual statements of list price in eligible TV ads.
The price would reflect a typical 30-day regimen or course of treatment and be anchored to the first day of the quarter in which the ad airs. The law also reserves authority to define the scope of applicability, formatting, enforcement mechanisms, and whether to include additional price information in regulations.
These rules would apply to drugs and biologics for which payment is available under Medicare or Medicaid (Title XVIII or XIX).
At a Glance
What It Does
The bill requires the HHS Secretary, via the CMS Administrator, to issue regulations within one year that compel direct-to-consumer TV advertising for qualifying drugs/biologics to include a truthful list price statement for a typical 30-day regimen or course of treatment, set as of the quarter’s first day.
Who It Affects
Direct-to-consumer drug and biologic ads on television (and related platforms), manufacturers marketing those products for Medicare/Medicaid populations, advertisers, and the media networks that air the ads.
Why It Matters
It introduces a mandatory price signal in DTCA, aiming to curb confusion over drug costs and help consumers compare options, while preserving regulatory flexibility to adjust scope and enforcement over time.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The act centers on price transparency in advertising for prescription drugs and certain biologics. It directs the Secretary of Health and Human Services, through the CMS Administrator, to draft rules within one year that require truthful, non-misleading textual statements of the list price in direct-to-consumer television advertising for drugs and biologics paid for under Medicare or Medicaid.
The required price statement must reflect the list price for a typical 30-day regimen or course of treatment and must be determined as of the first day of the quarter when the ad is aired. The implementing regulations would also decide whether the requirement should extend to other forms of advertising, how the price statement should be presented, what enforcement mechanics will apply, and whether additional price information should be included.
The bill does not specify penalties; enforcement approaches would be for the Administrator to determine.
The Five Things You Need to Know
The bill requires the Secretary of Health and Human Services to issue regulations within one year to mandate price statements in DTCA for eligible drugs and biologics.
The price statement must reflect the list price for a typical 30-day regimen or course of treatment, as of the first day of the quarter.
Regulations may extend to other forms of advertising, define the format, and set enforcement mechanisms.
The price disclosure applies to direct-to-consumer TV ads for drugs/biologics with Medicare/Medicaid payment.
Enforcement mechanisms are not specified in the bill and would be determined by the Administrator.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Section 1 designates the act as the Plain Prescription Prices Act, establishing its official name for references in law and policy analysis.
Regulating pricing disclosures in direct-to-consumer advertising
Section 2(a) requires the Secretary of Health and Human Services, through the Administrator of CMS, to promulgate regulations within one year that require a truthful and not misleading textual statement of the list price in direct-to-consumer television advertisements for prescription drugs and biological products for which payment is available under Medicare or Medicaid. The price statement must show the list price for a typical 30-day regimen or course of treatment and be determined on the first day of the quarter in which the ad airs. Section 2(b) grants the Administrator the authority to decide whether the regulations should apply to additional advertising forms, the manner and format of the textual statement, appropriate enforcement mechanisms, and whether the textual statements should include other price information as appropriate.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare and Medicaid beneficiaries viewing DTCA who gain price visibility to inform treatment choices and budgeting
- Private-plan members and other insured patients who compare costs across therapies
- Payers and employers managing drug costs who could leverage price disclosures for formulary decisions and budgeting
- Clinicians and pharmacists who counsel patients on affordability and treatment options with price context
- Advertising platforms and broadcasters seeking clearer, standardized compliance expectations
Who Bears the Cost
- Drug manufacturers required to incorporate price statements into ads, potentially increasing production and compliance costs
- Advertising agencies and media networks implementing price disclosures and ensuring accuracy
- Regulatory agencies (HHS/CMS) operationally supporting rulemaking, monitoring, and enforcement
- Payers and employers may incur costs in payer communications and patient education related to price information
Key Issues
The Core Tension
The central tension is between providing transparent, comparable price information to consumers and preserving market flexibility for manufacturers and advertisers. Requiring a standard, publicly visible price for a drug could influence demand and pricing strategies, while regulators must balance accuracy, format, and enforceability against potential marketing disruption and costs.
The bill creates a clear baseline for price transparency in DTCA but raises practical questions about price data accuracy, the definition of ‘list price’ across payers and negotiated discounts, and the potential impact on marketing strategies. It relies on rulemaking to set the precise mechanics, which could lead to transitional costs for manufacturers and the media industry.
The statutory trigger—private, federally supported pricing data—may incentivize some stakeholders to push for broader applicability or different price disclosures in future amendments. The absence of an explicit penalty in the statute means enforcement will depend on the rules negotiated by the Administrator and may involve civil or administrative remedies established in implementing regulations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.